Jacobs Levy Equity Management, Inc Allakos Inc. Transaction History

Jacobs Levy Equity Management, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.18 $413,907 - $765,247	240,644 Added 781.03%	271,455 $741,000
Q3 2023 Nov 16, 2023	SELL	$2.13 - $5.55 $286,406 - $746,269	-134,463 Reduced 81.36%	30,811 $69,000
Q2 2023 Aug 14, 2023	SELL	$3.6 - $5.25 $76,604 - $111,714	-21,279 Reduced 11.41%	165,274 $720,000
Q1 2023 May 15, 2023	SELL	$4.3 - $8.27 $137,243 - $263,953	-31,917 Reduced 14.61%	186,553 $830,000
Q4 2022 Feb 14, 2023	BUY	$5.66 - $8.42 $1.24 Million - $1.84 Million	218,470 New	218,470 $1.84 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.